Key takeaways:
- Itch was lengthy misunderstood. Now, it’s a quickly rising area of analysis.
- Consultants focus on the science behind itch and the way a patient-centric strategy propelled the sphere to the place it’s immediately.
The story of power itch and its affect on high quality of life is one dermatologists have heard usually. Till not too long ago, remedy choices have been restricted.
Such was the case for Denise Thomma, an elementary college librarian and affected person of Shawn G. Kwatra, MD, the Joseph W. Burnett endowed professor and chair of dermatology on the College of Maryland Faculty of Drugs.
“I used to be severely itchy throughout my physique, in ache … coated in bloody scabs, embarrassed and depressed,” Thomma mentioned in a tearful speech about her battle with prurigo nodularis, a dysfunction characterised by intensely itchy nodules, at Kwatra’s 2025 endowed professor investiture ceremony. “Once I showered, I might sob. It damage a lot … it was a nightmare.”
Roughly 22% of individuals report experiencing power pruritus, or itch, outlined as lasting longer than 6 weeks, sooner or later of their lives, in line with a 2024 examine printed in JAMA. Like Thomma, these sufferers usually report harsh psychological comorbidities due to their itch. In a 2020 examine printed within the Journal of the American Academy of Dermatology, researchers noticed charges of despair and nervousness starting from 46% to 53%.
“Keep in mind, Dante positioned intractable itch on one of many ranges of hell,” Daniel Kaplan, MD, PhD, professor of dermatology on the College of Pittsburgh, informed Healio. “In case you are scratching, you can not discover peace … it’s actually a horrible situation to have.”
Good therapies to deal with itch have emerged solely not too long ago, in line with Kaplan, who describes the present panorama of itch analysis as “very thrilling.”
How did the sphere make such a leap in progress? To reply this, one should perceive the historical past of and science behind itch.
The historical past of itch analysis
In response to Brian S. Kim, MD, MTR, the Sol and Clara Kest professor of dermatology and vice chair of analysis at Icahn Faculty of Drugs at Mount Sinai and director of the Mark Lebwohl Middle of Neuroinflammation and Sensation, the sphere of itch was ignored for many years because of a confluence of misunderstandings and assumptions about itch.
Brian S. Kim
“Once we first began on this journey, lots of people thought that itch wasn’t necessary,” Kim informed Healio. “They thought it was too sophisticated; it was unsolvable. There was even the assumption that it wasn’t actually a factor … that itch is a few type of gentle type of ache.”
The concept the identical pathways that mediated ache additionally mediated itch was extensively accepted till a breakthrough discovery in 2007.
Within the examine, printed in Nature, researchers recognized the primary itch-specific gastrin-releasing peptide receptor pathway in mice, which capabilities completely independently of ache. This urged itch isn’t a kind of ache however is as a substitute a completely completely different sensation.
A 2009 examine by the identical authors confirmed this discovering in one other mouse mannequin, exhibiting that the ablation of gastrin-releasing peptide receptor-expressing neurons within the spinal twine suppressed itch whereas preserving ache reflexes.
Constructing on these research, researchers then started to have a look at how itch impacts every day life.
In 2021, Kwatra and colleagues performed a examine, printed within the Journal of Investigative Dermatology, that in contrast the health-related high quality of life and financial burden of varied illnesses. The burden of power pruritus was larger than emphysema, untreated osteoarthritis and Parkinson’s illness and was comparable with the burden of stroke, diabetes and coronary heart failure.
Blair Jenkins
“These are power situations that we deal with aggressively,” Blair Jenkins, MD, PhD, medical assistant professor of dermatology at Michigan Drugs, informed Healio. “But individuals report itch being much more difficult to take care of.”
In response to Kwatra’s examine, a person affected person with prurigo nodularis on common loses 5.5 years of life and shoulders a $274,921 lifetime financial burden. The financial value is “probably a big underestimation,” the researchers wrote as a result of it didn’t account for situations that checklist itch as a secondary symptom and didn’t weigh the intangible prices that accompany itch situations reminiscent of job productiveness losses, incapacity and extra.
Adolescents with extreme prurigo are thrice extra more likely to expertise suicidal ideation in contrast with these with out an itch dysfunction, in line with a 2012 examine printed in Acta Dermato-Venereologica. It is a price just like adolescents who expertise ache.
“I’ve many sufferers who’re suicidal, and I let all people learn about that as a result of we have to amplify the human voice,” Kwatra mentioned. “That’s actually the important thing to creating this entire area.”
The science behind scratching
Consultants have pinpointed the important thing drivers of itch and have come to grasp why the urge to scratch is so uncontrollable.
Led by Kaplan, a bunch of researchers realized that scratching usually “feels good,” suggesting the motion should have been evolutionarily preserved for a goal. To analyze why, they performed a examine, printed in Science in 2025, and found that scratching has therapeutic and protecting properties.
There are two sources for itch, Kaplan mentioned: Exogenous and endogenous.
“An exogenous supply can be one thing like an irritant that you simply get on the pores and skin that may straight set off itch neurons,” Kaplan mentioned. “An instance of this comes from the mite scabies.”
In response to Kaplan’s examine, the physique responds to irritants, like mites, by sending white blood cells, also referred to as mast cells, to combat off the exogenous supply, which causes the feeling of itch. The identical method an individual reacts to ache by tending to it, an individual reacts to itch by scratching.
The researchers discovered that the act of scratching alerts to the physique to ship extra mast cells to the affected space to remove the irritant. This additionally prompts a pleasurable sensation that the neurons then talk to the mind, thus perpetuating the itch cycle.
“We demonstrated that irritation that’s augmented by scratching truly gives a number protection profit by lowering the quantity of Staphylococcus aureus on the pores and skin,” Kaplan mentioned. “This implies that there’s a profit to scratching by selling an applicable immune response domestically.”
Shawn G. Kwatra
In response to Kwatra, scratching additionally brings evolutionary advantages to the inhabitants degree by signaling to others that they need to defend themselves as a result of there could also be a dangerous pathogen within the space.
“In some ways, itch is such a sublime system that our physique has created,” Kwatra mentioned. “Power itch is a standard sensation, nevertheless it has simply gone a bit of haywire.”
Endogenous itch components originate from throughout the physique when small molecules made by the host activate neurons within the pores and skin to set off itch.
“I name this the micro itch/scratch cycle,” Kwatra mentioned. “This micro itch/scratch cycle is characterised by peripheral nerves which can be very activated and launch neuropeptides like substance P and nerve progress issue that then stimulate these immune cells like eosinophils or basophils to launch a wide range of cytokines like interleukin-4, IL-31 and IL-13 that then additionally stimulate the nerves.”
In response to Kwatra, this triggers a suggestions loop between the immune system and neural system. The nerves that drive that response journey from thinly myelinated a-delta and unmyelinated C fibers within the dermis by means of the dorsal root ganglion, which is a part of the peripheral nervous system, over the spinal twine to the mind after which again round.
“It is a essential processing pathway,” Kwatra mentioned. “We all know that the pores and skin is peripherally concerned in itch response, however we additionally know that centrally you may have necessary mediation of itch.”
Understanding the mechanisms of itch has led researchers to understand that telling sufferers to easily keep away from scratching isn’t solely unfair, however not attainable.
“Telling a affected person to cease scratching doesn’t work,” Jenkins mentioned. “It’s an innate reflex that’s hardwired into our nervous system.”
Pipeline progress
To correctly tackle a affected person’s particular itch, physicians should first determine the itch’s etiology. In response to a 2013 examine in Dermatologic Remedy, there are 4 medical classes of itch:
- neurogenic and systemic itch, which ends from issues that have an effect on organ techniques aside from the pores and skin reminiscent of renal failure, liver illness and hematologic malignancies;
- psychogenic itch, which is brought on by a psychological dysfunction;
- neuropathic itch, which ends from nervous system dysfunction;
- and pruritoceptive itch, which is generated within the pores and skin, both by means of irritation or pores and skin harm, consists of exogeneous or endogenous sources and contains most situations encountered by dermatologists.
In response to Kaplan, there’s a further fifth class referred to as idiopathic itch, also referred to as power pruritus of unknown origin.
Kim mentioned there are a whole bunch of situations which have itch because the underlying symptom, with dermatologists managing most of them. They embody AD, prurigo nodularis, power spontaneous urticaria, allergic contact dermatitis and bullous pemphigoid.
“The checklist goes on and on and on,” Kim mentioned. “Itch is the most typical symptom in dermatology.”
In response to a 2023 examine printed within the Journal of the American Academy of Dermatology, half of sufferers with a major dermatologic analysis reported pruritus as a symptom, with 25% additionally reporting extreme pruritus.
Moreover, in a 2020 examine printed in Acta Dermato-Venereologica, researchers reported that of 26 dermatologic situations, prurigo ranked because the third most painful situation after hidradenitis suppurativa and leg ulcers.
“If you happen to mentioned, ‘I’m going to deal with every part in dermatology however the itch,’” Kim mentioned, “You’ll be, at finest, a fairly awful dermatologist.”
In the course of the previous decade, the FDA has authorised a number of therapies for itch-driven illnesses and altered the remedy panorama, in line with Kim. Choices embody:
- dupilumab (Dupixent, Sanofi/Regeneron), an IL-4 receptor blocker authorised in 2017 for reasonable to extreme eczema in adults and in 2022 for youngsters, in 2022 for reasonable to extreme prurigo nodularis in adults and in 2025 for power spontaneous urticaria;
- nemolizumab (Nemluvio, Galderma), an IL-31 inhibitor authorised in 2024 for each reasonable to extreme AD in sufferers aged 12 years and older and reasonable to extreme prurigo nodularis in adults;
- tralokinumab (Adbry, Leo Pharma), an IL-13 inhibitor that was first authorised in 2021 for adults with reasonable to extreme AD and later authorised once more in 2023 for pediatric sufferers;
- lebrikizumab (Ebglyss, Eli Lilly and Firm), one other IL-13 inhibitor authorised for eczema in adults and kids in 2024;
- abrocitinib (Cibinqo, Pfizer), a Janus kinase (JAK) inhibitor additionally authorised in 2022 for eczema in adults and in 2023 for youngsters;
- upadacitinib (Rinvoq, AbbVie), one other JAK inhibitor authorised in 2022 for AD in adults and kids; and
- topical ruxolitinib (Opzelura, Incyte Company), the primary topical JAK inhibitor authorised in 2021 for the remedy of AD.
In response to Kim, Nemluvio’s approval was pushed by the invention of IL-31 as the primary cytokine that acts as a neurotransmitter. Researchers additionally discovered IL-4R and JAK1 in sensory neurons, which supported the remaining approvals for these itchy situations.
Though there was lots of innovation in creating these medicine, in line with Kim, these therapies weren’t created with the intent of treating itch.
“They have been developed as a result of they have been intervening upon immune pathways that have been considered necessary in illnesses like eczema,” Kim mentioned. “What we have been capable of do is join these discoveries to itch, and that was serendipitous.”
Kim mentioned the way forward for itch analysis ought to goal the remaining unmet wants of itch situations “not by doubling down on what is understood,” however by bringing “one thing completely new and completely different.”
Creating therapies ‘optimized for itch’
In response to Kim, the following frontier in itch analysis is treating itch as a illness reasonably than a symptom of different situations.
“The present therapeutics weren’t optimized for itch,” Kim mentioned. “They have been designed as anti-inflammatory brokers that inadvertently deal with itch and have exercise on the nervous system. What we may do now could be reimagine medicine and design them with the intent of concentrating on the nervous system in a sturdy and remit method.”
For instance, Kim mentioned, a affected person with a failing liver generally experiences recalcitrant itch; nonetheless, that affected person might not but meet the factors for a liver transplant. Because the affected person waits, they proceed to expertise unrelenting itch — one thing that drives many to suicidal ideation, in line with Kim.
“These are essentially the most tragic instances as a result of they’re telling you they can not dwell like this, however docs say ‘No, you’re doing simply high-quality, we’re not going to switch your liver but,’” Kim mentioned. “Think about if we may inform these sufferers that whereas they wait for his or her new liver, they don’t need to itch? It could be life-altering.”
Kwatra mentioned latest developments in precision medication now permit for phenotyping itch sufferers, figuring out novel itch affected person cohorts for brand spanking new medical trials. For instance, a 2025 examine printed within the Journal of the American Academy of Dermatology discovered that power pruritus of unknown origin has parts of sort 2 irritation, particularly eosinophils and excessive IgE ranges. These information might pave the way in which for incipient medical trials on this and different orphan itch situations, Kwatra mentioned.
In response to Kim, the thought is that dermatologists may study to deal with itch for the sake of itch alone, the identical method ache is alleviated with painkillers. Alys Prescribed drugs, cofounded by Kim, is pursuing this purpose with a expertise that could possibly goal itch nerves selectively to silence itch pathways.
“Think about getting a remedy each 3 to six months, or possibly yearly, the place the itch is basically turned off,” Kim mentioned. “That’s what we’re going after.”
In response to Jenkins, future analysis also needs to give attention to “teasing aside mechanisms” for power pruritus of unknown origin as a result of there are at the moment no FDA-approved therapies for this situation.
Regardless of the remaining unmet wants, itch analysis has grown quickly previously few a long time.
“There was a fundamental science period for itch, and we are actually within the midst of a therapeutic time for itch, however we’re additionally coming into this golden age of itch,” Kwatra informed Healio.
On the Society for Investigative Dermatology, Kwatra’s lab is ready to disclose, for the primary time, a peripheral blood immunophenotyping of power itch of unknown origin, exhibiting the significance of IL-31 concentrating on, a breakthrough that would additional advance itch remedy, Kwatra mentioned.
Kim additionally expressed pleasure for numerous itch therapies within the pipeline, together with remibrutinib (Novartis), an investigational, oral Bruton’s tyrosine kinase inhibitor in growth for power spontaneous urticaria, and barzolvolimab (Celldex Therapeutics), an antibody that depletes mast cells for the remedy of a number of itchy situations reminiscent of power spontaneous urticaria, prurigo nodularis and AD.
“We’re setting the stage for future trials … with a give attention to getting that ‘why’ so we will have agility in our area to then quickly go from precision medication phenotyping in people to medical trials to approvals,” Kwatra mentioned. “That’s the place we’re proper now, and I’m really, genuinely very enthusiastic about this time.”
From its misunderstood roots to its booming remedy portfolio, the journey of itch analysis wouldn’t have been attainable if it weren’t for the advocates who realized the struggling of those sufferers.
In response to Kwatra, it was not till after Thomma’s emotional speech about her expertise with prurigo nodularis that many physicians within the viewers realized the debilitating nature of power itch.
“I had colleagues coming as much as me saying ‘I had no thought that folks undergo that a lot,’” Kwatra mentioned. “And the reality is, Thomma was not solely crying as a result of she had been struggling however as a result of we have been lastly capable of assist.”
In response to Kwatra, it’s not pure science that drives innovation. Reasonably, it’s highlighting the lived expertise of sufferers that should be heard.
“The areas which have the quickest innovation are led by leaders that target the ‘why’ of analysis,” Kwatra mentioned. “The story of itch can be a humanitarian story.”
To proceed seeing progress on this area, Kwatra encourages dermatologists to maintain sufferers on the middle of their analysis, by no means forgetting the significance of their perspective.
For extra info:
Blair Jenkins, MD, PhD, will be reached at dermatology@healio.comand on X @DrBlairJenkins.
Brian S. Kim, MD, MTR, will be reached at itchdoctor@mountsinai.org and on X @itchdoctor.
Daniel Kaplan, MD, PhD, will be reached at dankaplan@pitt.edu.
Shawn G. Kwatra, MD, will be reached at dermatology@healio.com and on X @drshawnkwatra.
References:
- Adbry FDA Approval Historical past. https://www.medicine.com/historical past/adbry.html. Up to date June 24, 2025. Accessed Could 4, 2024.
- Butler DC, et al. JAMA. 2024;doi:10.1001/jama.2024.4899.
- Cibinqo FDA Approval Historical past. https://www.medicine.com/historical past/cibinqo.html. Up to date Feb. 28. 2023. Accessed Could 4, 2025.
- Dupixent FDA Approval Historical past. https://www.medicine.com/historical past/dupixent.html. Up to date April 23, 2025. Accessed Could 4, 2025.
- Ebglyss FDA Approval Historical past. https://www.medicine.com/historical past/ebglyss.html. Up to date Sept. 16, 2024. Accessed Could 4, 2025.
- Garibyan L, et al. Dermatol Ther. 2013;doi:10.1111/dth.12025.
- Golpanian RS, et al. J Am Acad Dermatol. 2020;doi:10.1016/j.jaad.2020.06.506.
- Halvorsen JA, et al. Acta Derm Venereol. 2012;doi:10.2340/00015555-1251.
- Investiture ceremony awarding Shawn G. Kwatra, MD. https://www.medschool.umaryland.edu/kwatrainvestiture/. Revealed April 15, 2025. Accessed Could 4, 2025.
- Liu AW, et al. Science. 2025;doi:10.1126/science.adn939.
- Nemluvio FDA Approval Historical past. https://www.medicine.com/historical past/nemluvio.html. Up to date Dec. 17, 2024. Accessed Could 4, 2025.
- Opzelura FDA Approval Historical past. https://www.medicine.com/historical past/opzelura.html. Up to date July 20, 2022. Accessed Could 4, 2025.
- Rinvoq FDA Approval Historical past. https://www.medicine.com/historical past/rinvoq.html. Up to date Dec. 9, 2024. Accessed Could 4, 2025.
- Roth YS, et al. J Am Acad Dermatol. 2022;doi: 10.1016/j.jaad.2021.07.076.
- Sampogna F, et al. Acta Derm Venereol. 2020;doi: 10.2340/00015555-3477.
- Solar YG, et al. Nature. 2007;doi:10.1038/nature06029.
- Solar YG, et al. Science. 2009;doi:10.1126/science.1174868.
- Wang F, et al. Immunity. 2020;doi:10.1016/j.immuni.2020.04.008.
- Whang KA, et al. J Make investments Dermatol. 2021;doi:10.1016/j.jid.2020.08.020.
